论文部分内容阅读
大多数何杰金氏病(HD)患者可通过化疗和/或放疗治愈,但仍有部分病人复发,最终导致补救化疗(SC),效果不佳而难以取得治愈.为此自身骨髓移植(ABMT)作为替代SC的手段应运而生.作者探讨了ABMT的最佳时机,以便使临床医师适时选择最佳治疗手段.作者假设了一个25岁的HD患者,经联合化疗后于一年内复发,分别以下列五种模型作为补救治疗方案:①在首次复发时应立即进行ABMT;②在SC取得完全缓解后进行ABMT;③在SC缓解后并于第二次复发时或SC无效时进行ABMT;④SC后不论效果如何均进行ABMT;⑤单用SC.同时综合了1980～1991年17份资料完整的国际英文版文献报道,分别予以归纳并进行了统计分析.采用完全缓解、部分缓解及死于治疗三种结果判断疗效,并从初治方案、平均生存时间、年生存费用、预后危险因素等方面进行探讨分析.
Most patients with Hodgkin’s disease (HD) can be cured by chemotherapy and / or radiotherapy, but some patients still have recurrences that eventually lead to remedial chemotherapy (SC), which is ineffective and difficult to cure. For this reason, their own bone marrow transplant (ABMT ) As a means to replace SC came into being.The authors discussed the best timing for ABMT in order to allow clinicians to choose the best treatment at the right time.The authors hypothesized that a 25 year old HD patient who relapsed within one year The following five models as remedial treatment: ① ABMT should be carried out immediately on the first relapse; ② ABMT after complete remission of SC; ③ ABMT after SC remission and at the second relapse or when SC is ineffective; ④ SC Regardless of the effect after the ABMT; ⑤ SC alone. At the same time, from 1980 to 1991, 17 complete international English literature reported, were summarized and analyzed statistically .Using complete remission, partial remission and died of treatment Three results to determine the efficacy, and from the initial treatment plan, the average survival time, cost of living, prognostic risk factors and other aspects of the analysis.